<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Gastroenterol Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Gastroenterol Hepatol</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</journal-title></journal-title-group><issn pub-type="ppub">1542-3565</issn><issn pub-type="epub">1542-7714</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10872845</article-id><article-id pub-id-type="pmcid-ver">PMC10872845.319</article-id><article-id pub-id-type="pmcaid">10872845</article-id><article-id pub-id-type="pmcaiid">10872845</article-id><article-id pub-id-type="manuscript-id">NIHMS1930439</article-id><article-id pub-id-type="pmid">37678488</article-id><article-id pub-id-type="doi">10.1016/j.cgh.2023.07.031</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1930439</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1930439</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Cannabinoids and the GI Tract</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Camilleri</surname><given-names initials="M">Michael</given-names></name><degrees>M.D., D.Sc.</degrees></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zheng</surname><given-names initials="T">Ting</given-names></name><degrees>M.D.</degrees></contrib><aff id="A1">Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA</aff></contrib-group><author-notes><fn fn-type="con" id="FN1"><p id="P1"><underline><bold>Authors&#8217; contributions</bold></underline>: Both authors drafted and finalized the manuscript.</p></fn><corresp id="CR1"><underline><bold>Address for correspondence</bold></underline>: Michael Camilleri, M.D., Mayo Clinic, 200 First St. S.W., Charlton Bldg., Rm. 8-110, Rochester, MN 55905, USA, Telephone: 507-266-2305, <email>camilleri.michael@mayo.edu</email></corresp><fn fn-type="COI-statement" id="FN2"><p id="P52"><underline><bold>Disclosures</bold></underline>: The authors have no conflicts of interest.</p></fn></author-notes><pub-date pub-type="ppub"><month>12</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>09</day><month>9</month><year>2023</year></pub-date><volume>21</volume><issue>13</issue><issue-id pub-id-type="pmc-issue-id">455926</issue-id><fpage>3217</fpage><lpage>3229</lpage><pub-history><event event-type="nihms-submitted"><date><day>10</day><month>09</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>12</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-01 00:25:14.133"><day>01</day><month>12</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1930439.pdf"/><abstract id="ABS1"><p id="P2">The synthesis and degradation of endocannabinoids, location of cannabinoid (CB) receptors, and cannabinoid mechanisms of action on immune/inflammatory, neuromuscular, and sensory functions in digestive organs are well documented. CB<sub>2</sub> mechanisms are particularly relevant in immune and sensory functions. Increasing use of cannabinoids in the USA is impacted by social determinants of health including racial discrimination which is associated with tobacco and cannabis co-use, and combined use disorders. Several conditions associated with emesis are related to cannabinoid use, including cannabinoid hyperemesis or withdrawal, cyclic vomiting syndrome, nausea and vomiting of pregnancy. Cannabinoids generally inhibit gastrointestinal motor function; yet they relieve symptoms in patients with gastroparesis and diverse nausea syndromes. Cannabinoid effects on inflammatory mechanisms have shown promise in relatively small placebo-controlled studies in reducing disease activity and abdominal pain in patients with inflammatory bowel disease (IBD). Cannabinoids have been studied in disorders of motility, pain, and disorders of gut brain interaction. The CB<sub>2</sub> receptor agonist, cannabidiol, reduced total Gastroparesis Cardinal Symptom Index and increased ability to tolerate a meal in patients with gastroparesis appraised over 4 weeks of treatment. In contrast, predominant-pain endpoints in functional dyspepsia with normal gastric emptying were not significantly improved with cannabidiol. The CB<sub>2</sub> agonist, olorinab, reduced abdominal pain in IBD in an open-label trial and in constipation-predominant irritable bowel syndrome in a placebo-controlled trial. Cannabinoid mechanisms alter inflammation in pancreatic and liver diseases. In conclusion, cannabinoids, particularly agents affecting CB<sub>2</sub> mechanisms, have potential for inflammatory, gastroparesis, and pain disorders; however, the trials require replication and further understanding of risk-benefit to enhance use of cannabinoids in gastrointestinal diseases.</p></abstract><kwd-group><kwd>cannabis</kwd><kwd>gastroparesis</kwd><kwd>inflammatory bowel diseases</kwd><kwd>nausea</kwd><kwd>vomiting</kwd><kwd>pain disorders</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>